Johnson & Johnson has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its covid-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.This trial is currently enrolling participants in Spain and the United Kingdom; enrolment will commence shortly in the United States, the Netherlands and Canada, with Brazil and Argentina to follow.
Read more on livemint.com